Pregnancy-induced worsening of thrombocytopenia in a patient with type IIB von Willebrand's disease.
Thrombocytopenia has been reported in patients with type IIB von Willebrand's disease (vWd) during pregnancy. In the present work we report the behaviour of platelet count and von Willebrand factor (vWf) multimers in a pregnant type IIB vWd patient who presented with mild thrombocytopenia in the steady state. The evolution of pregnancy was associated with a progressive decrease of platelet count which showed its lowest value two days before delivery (20 x 10(9)/l). The tendency of the platelet count to decrease was suddenly reversed a few days later (77 x 10(9)/l). At the same time, the vWf multimeric pattern showed a strict but inverse correlation with the platelet count. In fact, a progressive increase in low and intermediate sized vWf multimers, which proceeded until platelets reached their minimum level, was noted. A few days after delivery, concomitant with the prompt platelet increase, low and intermediate multimers became decreased. During pregnancy, the patient's platelet showed additional increased responsiveness to ristocetin but did not demonstrate spontaneous platelet aggregation (SPA). On the contrary, the patient's plasma, collected both during and after pregnancy, caused normal platelets to aggregate spontaneously. SPA appeared completely blocked by an anti-GPIIb-IIIa monoclonal antibody (MAb), which recognized the binding site for fibrinogen, vWf and fibronectin. In contrast, a MAb against ristocetin-induced vWf binding site on GPIb did not affect SPA. These findings suggest that the common stimulus or stimuli, responsible for the pregnancy-induced decrease of platelet count and improvement of vWf multimeric pattern in type IIB vWd is strictly related to pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)
Casonato
A
A
Institute of Semeiotics, University of Padua Medical School, Italy.
Sartori
M T
MT
Bertomoro
A
A
Fede
T
T
Vasoin
F
F
Girolami
A
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology; D001780:Blood Coagulation Tests; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count; D010980:Platelet Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood*; D012310:Ristocetin / Q000494:pharmacology; D013921:Thrombocytopenia / Q000209:etiology*; D014842:von Willebrand Diseases / Q000097:blood / Q000145:classification / Q000150:complications*; D014841:von Willebrand Factor / Q000378:metabolism
D000911:Antibodies, Monoclonal; D005353:Fibronectins; D010980:Platelet Membrane Glycoproteins; D014841:von Willebrand Factor; D012310:Ristocetin; D005340:Fibrinogen